IN BRIEF: MGC Pharmaceuticals gets ArtemiC trial boost

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says results from ...

Alliance News 7 May, 2021 | 6:16PM
Email Form Facebook Twitter LinkedIn RSS

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says results from probe into ArtemiC product show it is effective in preventing increased production of cytokine. MGC says cytokine storms are "believed to be the main reason for mortality in severe Covid-19 patients". "The findings from the phase II clinical trials which are supported by the completed preclinical trial results, continue to demonstrate the effectiveness of ArtemiC in treating patients with different variants of Covid-19," MGC Managing Director Roby Zomer says.

Current stock price: 3.67 pence

Year-to-date change: up 54% since February 9

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
MGC Pharmaceuticals Ltd 22.00 GBX 0.00 -
MGC Pharmaceuticals Ltd 0.43 AUD 4.88 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures